Hyperthyroidism in Patients with Graves' Ophthalmopathy, and Thyroidal, Skeletal and Eye Muscle Specific Type 2 Deiodinase Enzyme Activities.

Graves' ophthalmopathy is characterized by hyperthyroidism, which is associated with higher serum T3 levels than T4 due to deiodinase enzymes.The effect of Graves' patient's sera (n=52) with elevated thyroid hormone and TSH receptor or thyroid peroxidase antibody (anti-TPO) levels was investigated on thyroidal, skeletal and eye muscle type 2 deiodinase enzyme (DII) activities. DII activities were measured with 125I-T4 substrate, while thyroid hormone and antibody levels with immunoassays.In Graves' ophthalmopathy, sera with elevated FT4 or FT3 levels reduced DII activites remarkably in all tissue fractions. Thyroidal DII activities were lower than those using eye muscle fraction (0.6±0.22 vs 1.14±0.43 pmol/mg/min, P<0.006). Effect of sera with increased FT3 levels demonstrated also reduced DII activities in patients with Graves' ophthalmopathy after methimazole therapy compared to those who had no ophthalmopathy (2.88±2 vs 20.42±11.82 pmol/mg/min, P<0.006 for thyroidal fraction, 4.07±2.72 vs 29.22±15.46 pmol/mg/min, P<0.004 for skeletal muscle, 5.3±3.47 vs 37.87±18.82 pmol/mg/min, P<0.003 for eye muscle). Hyperthyroid sera with TSH receptor antibodies resulted in increased DII activities, while sera with anti-TPO antibodies were connected to lower DII activities in Graves' ophthalmopathy.In summary, the actions of hyperthyroid sera derived from patients with Graves' disease were tested on tissue-specific DII activities. Elevated FT4 level-induced DII inactivation is present in Graves' ophthalmopathy, which seems to be also present at the beginning of methimazole therapy. Stimulating TSH receptor antibiodies increased DII activities via their nongenomic effects using sera of hyperthyroid Graves' ophthalmopathy, but anti-TPO antibodies could influence DII activities via altering FT4 levels.

[1]  K. Tsunekawa,et al.  Type 2 Iodothyronine Deiodinase Activity Is Required for Rapid Stimulation of PI3K by Thyroxine in Human Umbilical Vein Endothelial Cells. , 2015, Endocrinology.

[2]  A. Bianco,et al.  Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine. , 2015, The Journal of clinical investigation.

[3]  J. Harney,et al.  The selective loss of the type 2 iodothyronine deiodinase in mouse thyrotrophs increases basal TSH but blunts the thyrotropin response to hypothyroidism. , 2015, Endocrinology.

[4]  J. Werneck-de-Castro,et al.  Role of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone signaling. , 2013, Biochimica et biophysica acta.

[5]  Csaba Fekete,et al.  Coordination of hypothalamic and pituitary T3 production regulates TSH expression. , 2013, The Journal of clinical investigation.

[6]  M. Mori,et al.  A novel mechanism for the inhibition of type 2 iodothyronine deiodinase by tumor necrosis factor α: involvement of proteasomal degradation. , 2013, Endocrine journal.

[7]  A. Bianco,et al.  Type 2 deiodinase at the crossroads of thyroid hormone action. , 2011, The international journal of biochemistry & cell biology.

[8]  J. Bassett,et al.  Local control of thyroid hormone action: role of type 2 deiodinase Deiodinases: the balance of thyroid hormone , 2011 .

[9]  M. Dentice,et al.  Local impact of thyroid hormone inactivation Deiodinases: the balance of thyroid hormone , 2011 .

[10]  S. Wajner,et al.  Deiodinases: the balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology and disease. , 2011, The Journal of endocrinology.

[11]  M. Dentice,et al.  Deiodinases: the balance of thyroid hormone: local impact of thyroid hormone inactivation. , 2011, The Journal of endocrinology.

[12]  J. Bassett,et al.  Deiodinases: the balance of thyroid hormone: local control of thyroid hormone action: role of type 2 deiodinase. , 2011, The Journal of endocrinology.

[13]  M. Schott.  Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with 3,5,3′-triiodothyronine-predominant Graves' disease , 2011 .

[14]  A. Bianco,et al.  Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment. , 2010, Endocrinology.

[15]  Donald L St Germain,et al.  Minireview: Defining the roles of the iodothyronine deiodinases: current concepts and challenges. , 2009, Endocrinology.

[16]  Csaba Fekete,et al.  Negative feedback regulation of hypophysiotropic thyrotropin-releasing hormone (TRH) synthesizing neurons: Role of neuronal afferents and type 2 deiodinase , 2007, Frontiers in Neuroendocrinology.

[17]  P. Laurberg,et al.  Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. , 2007, The Journal of clinical endocrinology and metabolism.

[18]  A. J. Szentmiklósi,et al.  Immunohistochemical Studies Using Immunized Guinea Pig Sera with Features of Anti-Human Thyroid, Eye and Skeletal Antibody and Graves’ Sera , 2007, Journal of Clinical Immunology.

[19]  Thomas S. Scanlan,et al.  Rapid nongenomic actions of thyroid hormone , 2006, Proceedings of the National Academy of Sciences.

[20]  J. Harney,et al.  Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. , 2005, The Journal of clinical investigation.

[21]  T. Visser,et al.  Inhibition of pituitary type 2 deiodinase by reverse triiodothyronine does not alter thyroxine-induced inhibition of thyrotropin secretion in hypothyroid rats. , 2005, European journal of endocrinology.

[22]  W. Klootwijk,et al.  Characteristics and thyroid state-dependent regulation of iodothyronine deiodinases in pigs. , 2004, Endocrinology.

[23]  T. Visser,et al.  Thyroid over-expression of type 1 and type 2 deiodinase may account for the syndrome of low thyroxine and increasing triiodothyronine during propylthiouracil treatment. , 2003, European journal of endocrinology.

[24]  J. Harney,et al.  In vivo dimerization of types 1, 2, and 3 iodothyronine selenodeiodinases. , 2003, Endocrinology.

[25]  S. Fiering,et al.  Targeted disruption of the type 2 selenodeiodinase gene (DIO2) results in a phenotype of pituitary resistance to T4. , 2001, Molecular endocrinology.

[26]  H. Mizuma,et al.  Expression and Regulation of Type II Iodothyronine Deiodinase in Human Thyroid Gland1 , 2001 .

[27]  H. Mizuma,et al.  Thyroid Hormone Activation in Human Vascular Smooth Muscle Cells: Expression of Type II Iodothyronine Deiodinase , 2001, Circulation research.

[28]  H. Mizuma,et al.  Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. , 2001, Endocrinology.

[29]  J. Harney,et al.  Distinct subcellular localization of transiently expressed types 1 and 2 iodothyronine deiodinases as determined by immunofluorescence confocal microscopy. , 2000, Endocrinology.

[30]  L. Czirják,et al.  Euthyroid sick syndrome and inhibitory effect of sera on the activity of thyroid 5'-deiodinase in systemic sclerosis. , 2000, Clinical and experimental rheumatology.

[31]  J. Harney,et al.  Selective proteolysis of human type 2 deiodinase: a novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. , 2000, Molecular Endocrinology.

[32]  J. Harney,et al.  Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme's active center. , 2000, Endocrinology.

[33]  Y Hosoi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Expression and Regulation of Type II Iodothyronine Deiodinase in Cultured Human Skeletal Muscle Cells* , 2022 .

[34]  N. Farid,et al.  Effect of anti-thyroid peroxidase (TPO) antibodies on TPO activity measured by chemiluminescence assay. , 1997, Clinical chemistry.

[35]  W. Wiersinga,et al.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy , 1997, Clinical endocrinology.

[36]  Y. Mori,et al.  Synergistic effect of thyroid hormone and thyrotropin on iodothyronine 5'-deiodinase in FRTL-5 rat thyroid cells. , 1990, Endocrinology.

[37]  L. Degroot,et al.  Identification of a thyroid microsomal antigen by Western blot and immunoprecipitation. , 1985, The Journal of clinical endocrinology and metabolism.

[38]  E. Kaptein,et al.  Peripheral tissue mechanism for maintenance of serum triiodothyronine values in a thyroxine-deficient state in man. , 1984, The Journal of clinical investigation.

[39]  S. Werner.  Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. , 1977, The Journal of clinical endocrinology and metabolism.

[40]  J. Hershman,et al.  Propylthiouracil blocks extrathyroidal conversion of thyroxine to triiodothyronine and augments thyrotropin secretion in man. , 1975, The Journal of clinical investigation.

[41]  P. Larsen,et al.  Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents. , 1974, The Journal of clinical investigation.

[42]  R. Estabrook,et al.  Improvements in the isolation procedure for thyroid peroxidase: nature of the heme prosthetic group. , 1970, Archives of biochemistry and biophysics.

[43]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.